PDCD1 and neoplasm: The efficacy of ICIs, particularly those targeting the PD-1/PD-L1 axis, is diminished in tumors with low PD-L1 expression due to the reduced interaction between PD-1 on T cells and PD-L1 on tumor cells [67].